The guidelines do not recommend adjuvant therapy for PDGFRA D842V-mutated GISTs and GISTs without C-kit or PDGFRA mutations (Wild-type GIST) because of the relatively indolent nature as well as their lack of imatinib responsiveness [36,83,104]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.